{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:21:57Z","timestamp":1784863317750,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-022-02304-0","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:09:25Z","timestamp":1663862965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial"],"prefix":"10.1007","author":[{"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-1296","authenticated-orcid":false,"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akichika","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Tatsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"1","key":"2304_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15\u201322.","journal-title":"Cephalalgia"},{"key":"2304_CR2","doi-asserted-by":"crossref","unstructured":"Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021:37(11):1945\u201355.","DOI":"10.1080\/03007995.2021.1971179"},{"issue":"1","key":"2304_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8\u201319.","journal-title":"Headache"},{"issue":"1","key":"2304_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther. 2022;11(1):205\u201322.","journal-title":"Neurol Ther"},{"issue":"1","key":"2304_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68.","journal-title":"J Headache Pain"},{"issue":"10","key":"2304_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/head.12941","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2016;56(10):1635\u201348.","journal-title":"Headache"},{"issue":"10","key":"2304_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159\u201369.","journal-title":"Cephalalgia"},{"issue":"1","key":"2304_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action\u2014review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71.","journal-title":"J Headache Pain"},{"issue":"7","key":"2304_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase\u00a03 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894\u2013904.","journal-title":"Brain"},{"issue":"24","key":"2304_CR10","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase\u00a03 randomized study. Neurology. 2018;91(24):e2222\u201332.","journal-title":"Neurology"},{"issue":"1","key":"2304_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0333102419889350","volume":"40","author":"K Knievel","year":"2020","unstructured":"Knievel K, Buchanan AS, Lombard L, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19\u201327.","journal-title":"Cephalalgia"},{"issue":"8","key":"2304_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/head.13897","volume":"60","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Vasudeva R, Krege JH, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks. Headache. 2020;60(8):1601\u201315.","journal-title":"Headache"},{"issue":"5","key":"2304_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M. Phase\u00a02 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache. 2021;61(5):755\u201365.","journal-title":"Headache"},{"key":"2304_CR14","doi-asserted-by":"crossref","unstructured":"The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808.","DOI":"10.1177\/0333102413485658"},{"key":"2304_CR15","unstructured":"Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(suppl. 1):9\u2013160."},{"key":"2304_CR16","doi-asserted-by":"crossref","unstructured":"Joint Committee for Comprehensive Risk Management Chart for the Prevention of Cerebro- and Cardiovascular Diseases. Comprehensive risk management chart for the prevention of cerebro- and cardiovascular diseases. Nihon Naika Gakkai Zasshi. 2015;104(4):824\u201364.","DOI":"10.2169\/naika.104.824"},{"key":"2304_CR17","unstructured":"Japan Headache Society. Chronic headache practice guideline 2013. https:\/\/www.neurology-jp.org\/guidelinem\/ch\/documents\/preface.pdf. Accessed 3 Jan 2022."},{"key":"2304_CR18","doi-asserted-by":"crossref","unstructured":"Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6\u201338.","DOI":"10.1177\/0333102411417901"},{"issue":"1","key":"2304_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","volume":"20","author":"LS Loo","year":"2019","unstructured":"Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase\u00a03 trials. J Headache Pain. 2019;20(1):84.","journal-title":"J Headache Pain"},{"key":"2304_CR20","first-page":"109","volume":"8","author":"S Munjal","year":"2016","unstructured":"Munjal S, Gautam A, Rapoport AM, Fisher DM. The effect of weight, body mass index, age, sex, and race on plasma concentrations of subcutaneous sumatriptan: a pooled analysis. Clin Pharmacol. 2016;8:109\u201316.","journal-title":"Clin Pharmacol"},{"key":"2304_CR21","unstructured":"Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211765Orig1s000MedR.pdf. Accessed 27 Apr 2022."},{"issue":"1","key":"2304_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12883-020-01848-4","volume":"20","author":"K Hirata","year":"2020","unstructured":"Hirata K, Ueda K, Ye W, et al. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme. BMC Neurol. 2020;20(1):274.","journal-title":"BMC Neurol"},{"issue":"5","key":"2304_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414\u201325.","journal-title":"Headache"},{"issue":"1","key":"2304_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/17425255.2018.1416097","volume":"14","author":"A Gonzalez-Hernandez","year":"2018","unstructured":"Gonzalez-Hernandez A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalon CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018;14(1):25\u201341.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"2304_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","volume":"20","author":"RE Shapiro","year":"2019","unstructured":"Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase\u00a03 trials. J Headache Pain. 2019;20(1):90.","journal-title":"J Headache Pain"},{"issue":"1","key":"2304_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40122-020-00223-y","volume":"10","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, et al. Unmet needs in Japanese patients who report insufficient efficacy with triptans for acute treatment of migraine: retrospective analysis of real-world data. Pain Ther. 2021;10(1):415\u201332.","journal-title":"Pain Ther"},{"issue":"2","key":"2304_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1526-4610.2005.05031.x","volume":"45","author":"DW Dodick","year":"2005","unstructured":"Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache. 2005;45(2):156\u201362.","journal-title":"Headache"},{"issue":"7","key":"2304_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1177\/0333102409354390","volume":"30","author":"F Sheftell","year":"2010","unstructured":"Sheftell F, Almas M, Weeks R, Mathew NT, Pitman V, Lipton RB. Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia. 2010;30(7):838\u201346.","journal-title":"Cephalalgia"},{"issue":"2","key":"2304_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/head.12978","volume":"57","author":"K Maasumi","year":"2017","unstructured":"Maasumi K, Tepper SJ, Kriegler JS. Menstrual migraine and treatment options: review. Headache. 2017;57(2):194\u2013208.","journal-title":"Headache"},{"issue":"4","key":"2304_CR30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1526-4610.2010.01625.x","volume":"50","author":"EA MacGregor","year":"2010","unstructured":"MacGregor EA, Victor TW, Hu X, et al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010;50(4):528\u201338.","journal-title":"Headache"},{"issue":"1","key":"2304_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/03331024211048507","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Krege JH, Lombard L, et al. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: findings from the CENTURION study. Cephalalgia. 2022;42(1):20\u201330.","journal-title":"Cephalalgia"},{"issue":"3","key":"2304_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1212\/01.WNL.0000133207.70312.30","volume":"63","author":"H Christoph-Diener","year":"2004","unstructured":"Christoph-Diener H, Ferrari M, Mansbach H. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology. 2004;63(3):520\u20134.","journal-title":"Neurology"},{"issue":"1","key":"2304_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1468-2982.2007.01457.x","volume":"28","author":"HC Diener","year":"2008","unstructured":"Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia. 2008;28(1):35\u201340.","journal-title":"Cephalalgia"},{"issue":"9","key":"2304_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1468-2982.2005.00981.x","volume":"25","author":"JL Brandes","year":"2005","unstructured":"Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25(9):735\u201342.","journal-title":"Cephalalgia"},{"issue":"4","key":"2304_CR35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1526-4610.2007.00756.x","volume":"47","author":"FG Freitag","year":"2007","unstructured":"Freitag FG, Finlayson G, Rapoport AM, et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache. 2007;47(4):519\u201330.","journal-title":"Headache"},{"issue":"3","key":"2304_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/0333102411433042","volume":"32","author":"M Lant\u00e9ri-Minet","year":"2012","unstructured":"Lant\u00e9ri-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia. 2012;32(3):226\u201335.","journal-title":"Cephalalgia"},{"issue":"8","key":"2304_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0333102419855080","volume":"39","author":"JH Krege","year":"2019","unstructured":"Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from phase\u00a03 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia. 2019;39(8):957\u201366.","journal-title":"Cephalalgia"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02304-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02304-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02304-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T17:07:32Z","timestamp":1664989652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02304-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":37,"alternative-id":["2304"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02304-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}